Anti-Human PD-L1 (CD274)

Anti-Human PD-L1 (CD274)

Product No.: B560

[product_table name="All Top" skus="B560"]

- -
- -
Target
PD-L1
Product Type
Polyclonal Antibody
Alternate Names
B7 Homolog 1, B7-H, MGC142294, MGC142296, PDCD1L1, PDCD1LG1, PDL1
Applications
B
,
ELISA Indirect
,
IHC
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Goat
Immunogen
Purified Recombinant Human B7-H1 (Accession # Q9NZQ7)
Endotoxin Level
<0.1 EU/µg as determined by the LAL method
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.4 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
State of Matter
Lyophilized
Storage and Handling
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
Indirect ELISA: This antibody can be used in an indirect detection ELISA at 0.5-1.0 µg/ml with a suitable second step reagent such as PN:G505. The detection sensitivity of this indirect ELISA for Human B7-H1 is approximately 0.1 ng/well.
Western Blotting: To detect Human B7-H1 this polyclonal antibody can be used at a concentration of 2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as PN:G505 and a chromogenic substrate such as PN:T343. The detection limit for Human B7-H1 is 0.5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:B530.
Additional Applications Reported In Literature ?
Immunohistochemistry: Suitable for use at concentration of 5-15 µg/mL.
Blocking: In a functional ELISA, 1-5 µg/mL of this antibody will block 50% of the binding of 100 ng/mL of biotinylated Recombinant Human PD-L1/B7-H1 to immobilized Recombinant Mouse PD-1 Fc Chimera coated at 1 µg/mL (100 µL/well). At 50 µg/mL, this antibody will block >90% of the binding.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Goat Anti-Human B7-Homolog 1 (B7-H1) recognizes Human B7-H1. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
PubMed
NCBI Gene Bank ID

References & Citations

B
Indirect Elisa Protocol
IHC
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.